International Extranodal Lymphoma Study Group (ielsg)

This study is testing a treatment plan for a type of slow-growing cancer called MALT lymphoma. It combines two drugs, chlorambucil and rituximab, given as an initial intensive treatment. Patients who respond then receive rituximab alone as a long-term maintenance therapy for two …

This study aims to determine if radiation therapy is truly needed for patients with primary mediastinal B-cell lymphoma who have already responded well to chemotherapy. After completing chemotherapy, patients with negative PET scans (showing no active cancer) will be randomly ass…

This study is testing if a two-drug combination (rituximab plus zanubrutinib) works better and is as safe as a single drug (rituximab alone) for people with a specific type of blood cancer called splenic marginal zone lymphoma who haven't had treatment before. About 122 participa…

This study is testing the safety and effectiveness of combining two existing drugs, ibrutinib and rituximab, for people newly diagnosed with a slow-growing blood cancer called marginal zone lymphoma. The trial will enroll 175 adults who have not yet received any chemotherapy or i…

This trial is testing if a long course of the antibiotic doxycycline can control a rare type of eye lymphoma by treating a possible bacterial infection linked to the cancer. It is for adults newly diagnosed with early-stage lymphoma only in the eye area who have not had recent an…

This international study looks back at existing PET scan images from 496 marginal zone lymphoma patients to understand how well these scans help determine disease stage and predict treatment outcomes. Researchers are analyzing scans already taken during previous studies and routi…